CeriBell, Inc. (NASDAQ:CBLL) Receives Consensus Recommendation of “Moderate Buy” from Analysts

CeriBell, Inc. (NASDAQ:CBLL) has earned a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $24.6667.

A number of equities research analysts have commented on CBLL shares. BTIG Research reissued a “buy” rating and issued a $30.00 target price on shares of CeriBell in a report on Wednesday, January 28th. Canaccord Genuity Group increased their price target on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. JPMorgan Chase & Co. decreased their price objective on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. TD Cowen restated a “buy” rating on shares of CeriBell in a research report on Tuesday, December 9th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of CeriBell in a research report on Wednesday, October 8th.

CeriBell Stock Performance

NASDAQ CBLL opened at $20.15 on Thursday. The stock has a market capitalization of $747.48 million, a price-to-earnings ratio of -13.34 and a beta of 1.03. The business’s 50 day moving average is $21.05 and its two-hundred day moving average is $15.62. CeriBell has a 12-month low of $10.01 and a 12-month high of $26.04. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The firm had revenue of $22.59 million for the quarter, compared to the consensus estimate of $21.78 million. Research analysts expect that CeriBell will post -2.46 EPS for the current year.

Insider Activity at CeriBell

In other CeriBell news, VP David Foehr sold 5,556 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $22.60, for a total value of $125,565.60. Following the sale, the vice president owned 18,900 shares of the company’s stock, valued at approximately $427,140. This represents a 22.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Xingjuan Chao sold 79,000 shares of CeriBell stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $21.27, for a total value of $1,680,330.00. Following the transaction, the chief executive officer owned 741,248 shares of the company’s stock, valued at $15,766,344.96. This represents a 9.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 375,212 shares of company stock valued at $7,306,950 in the last 90 days. 20.10% of the stock is owned by corporate insiders.

Institutional Trading of CeriBell

Hedge funds have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in CeriBell in the third quarter valued at approximately $33,000. CWM LLC raised its position in CeriBell by 1,178.5% in the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after purchasing an additional 1,697 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after buying an additional 1,801 shares during the period. Ameritas Investment Partners Inc. raised its stake in shares of CeriBell by 97.5% during the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after purchasing an additional 1,256 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey increased its stake in CeriBell by 161.0% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock worth $106,000 after buying an additional 3,502 shares during the period.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.